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Abstract: Tuberculosis (TB) is the most deadly infectious disease globally. Although most
individuals achieve a cure, a substantial portion develop multi-drug resistant TB which is
exceedingly difficult to treat, and the number of effective agents is dwindling. Development
of new anti-tubercular medications is imperative to combat existing drug resistance and
accelerate global eradication of TB. Pretomanid (PA-824) represents one of the newest drug
classes (ie, nitroimidazooxazines) approved in 2019 by the United States Food and Drug
Administration as part of a multi-drug regimen (with bedaquiline and linezolid, BPaL) and
recommended by the World Health Organization (WHO) to treat extensively-resistant (XRTB) and multi-drug resistant tuberculosis (MDR-TB). Approval was granted through the
FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs, which acceler
ates approval for antimicrobial drugs used to treat life-threatening or serious infections in
a limited population with unmet need. This review details the pharmacology, efficacy, and
safety of this new agent and describes evidence to date for its role in the treatment of drug
resistant TB including published, ongoing, and planned studies.
Keywords: pretomanid, tuberculosis, antimicrobial, multi-drug resistant
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Tuberculosis (TB) is estimated to infect 25% of the world’s population and is the
most deadly infectious disease globally.1 Nearly 85% of individuals with TB
achieve a cure; however, a substantial portion of individuals develop drugresistant TB which has become increasingly difficult to treat, largely due to variant
strains exhibiting resistance to multiple medications.1 Development of new antitubercular medications is imperative to combat existing drug-resistance and accel
erate global eradication of TB.
Pretomanid (PA-824) represents one of the newest drug classes (ie, nitroimida
zooxazines) approved for the treatment of TB. Pretomanid was approved by the
United States Food and Drug Administration (FDA) in August 2019 as part of
a multi-drug regimen (with bedaquiline and linezolid, BPaL) to treat extensivelyresistant (XR-TB) and multi-drug resistant tuberculosis (MDR-TB). Approval was
granted through the FDA’s Limited Population Pathway for Antibacterial and
Antifungal Drugs, which accelerates approval for antimicrobial drugs used to
treat life-threatening or serious infections in a limited population with unmet
need. Since that time, pretomanid has also been approved for limited use in India
and granted marketing authorization by the European Medicines Agency (EMA).
This review will detail the pharmacology of this new agent and describe evidence to
Drug Design, Development and Therapy 2021:15 2815–2830
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date for its role in the treatment of drug resistant TB
including published, ongoing, and planned studies.

(Figure 2A).7 In MTb, NAP reduction is mediated by the
bacterial deazaflavin-dependent nitroreductase (Ddn).8
Ddn relies on the reduced form of cofactor F420 (ie
F420H2), as an electron donor. F420H2 is generated during
the oxidation of glucose-6-phosphate to 6-phosphogluco
nate which is mediated by F420-dependent glucose-6-phos
phate dehydrogenase (Fgd). Contributing to the
biosynthesis of F420 are the proteins fbiA, fbiB, fbiC,
and fbiD (Figure 2A).
Subsequent protonation of pretomanid can also gener
ate desnitro metabolites and nitrous acid which further
decompose to nitric oxide. One investigation demonstrated
that cellular nitric oxide production increases in a dosedependent manner following anaerobic co-incubation of
M. bovis cultures with pretomanid.8 It should be noted
that only the lowest pretomanid concentrations evaluated
in this study reflect those that can reasonably be expected
in the plasma at steady-state following administration of
the approved 200 mg once daily dose. Consequently, the
contribution of nitric oxide release to efficacy in myco
bacterial lesions and infected immune cells remains to be
confirmed. However, preclinical rat disposition data do
suggest that autoradiographic signals in lung 4 hours
after oral administration of [14C]pretomanid are approxi
mately 50% higher than observed in blood.9

Chemical Properties

Replicating Bacteria

Figure 1 Structural relationships between the nitroimidazoles, nitroimidazooxa
zoles, and nitroimidazopyrans.

Pretomanid represents the class of nitroimidazopyrans
(NAP) which are derivatives of nitroimidazoles such as
azomycin and metronidazole (Figure 1). The more
immediate precursor of pretomanid is Ciba-Geigy com
pound CGI-17341 which was originally investigated as
a radiosensitizer for chemotherapy and discovered to be
mutagenic. It also demonstrated antimycobacterial activity
which prompted the synthesis of several hundred bicyclic
nitroimidazooxazoles (eg, delamanid) and NAPs including
pretomanid that did not demonstrate mutagenicity. Readers
interested in details about NAP stereochemistry are
referred to the following references.2–6

Mechanism of Action
Non-Replicating Bacteria
Under anaerobic conditions, the putative mechanism of
action for nitroimidazole prodrugs involves reductive
“activation” within the mycobacteria to reactive nitro radi
cal anion intermediates that are capable of interacting with
cellular components and interrupting cellular respiration
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Pretomanid demonstrates the ability to inhibit protein and
lipid biosynthesis under conditions where nucleic acid
synthesis remains unaffected.2 One proposed mechanism
suggests that pretomanid reduces the availability of keto
mycolic acids, components of the cell wall lipid bilayer, by
impairing oxidative transformation of precursor hydroxy
mycolates (Figure 2B).2,10 Whether this reflects direct
action on the deazaflavin cofactor F420-dependent hydro
xymycolic acid dehydrogenase (fHMAD)11 or indirect
action upstream of this enzyme is unclear from these
reports.
A more recent study examining MTb metabolomic
signatures mid-log phase suggests that pretomanid targets
the pentose phosphate pathway resulting in the accumula
tion of phosphate sugars.12 This leads to the toxic accu
mulation of methylglyoxal, a highly reactive ketoaldehyde
that glycates nucleic acids and proteins prompting cellular
arrest.12,13 Given the redox relationship between Ddn and
Fgd illustrated in Figure 2A, this proposed mechanism
may impact latent bacteria as well as replicating bacteria.
Notably, this study confirms a mechanism of action wholly
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Figure 2 (A) Intracellular activation pathway for nitroimidazoles. (B) Keto mycolic acid synthesis pathway. Pretomanid blocks formation of keto mycolic acids, a component
of the cell wall, by impairing oxidation of precursor, hydroxymycolic acid.

distinct from other agents used to treat MTb including
ampicillin, ethambutol, ethionamide, isoniazid, kanamy
cin, linezolid, rifampin, and streptomycin.12

Mechanisms of Resistance
Nitroimidazopyran-resistant mutants do not efficiently
reduce nitroaromatic compounds and do not appear to
generate the polar reactive metabolites of pretomanid.2
For mutants selected in vitro, this inability to activate
pretomanid has been linked to sequence variations in the
same genes responsible for its activity, namely those
encoding Ddn, Fgd, and the proteins involved in F420
biosynthesis (fbiA, fbiB, fbiC) (Figure 2A).14–17
Resistance explained by sequence variations in these 5
genes accounted for 83% of the isolates examined in one
study (Ddn 29%, Fgd 7%, fbiA 19%, fbiB 2%, fbiC 26%).
The remaining 17% of isolates demonstrated no identifi
able sequence variations in these genes, suggesting the
presence of additional loci that mediate resistance.14
A more recent study may elucidate the missing
mechanism(s). An investigation of spontaneous mutants
isolated in vivo from a murine model attributed pretoma
nid resistance in 90% of isolates to the same 5 genes noted
previously, with a similar rank order (Ddn 12%, Fgd 4%,
fbiA 15%, fbiB 4%, fbiC 55%). In the remaining 10% of
isolates, the authors were able to attribute resistance to
sequence variations in what they identified as CofC
(RV2983). Wild-type Rv2983 paired with a variant

Drug Design, Development and Therapy 2021:15

RV2983 restored pretomanid susceptibility. Notably,
CofC appears to be the archaeal homolog of bacterial
fbiD18 and thus may also be involved in F420
biosynthesis.19
Though genes involved with the F420-dependent path
way play a role in managing oxidative stress, with limited
exception, they are not represented among those that
appear to be required for the growth and survival of
MTb.20–24 Functional or structural analogs of these pro
teins contribute to redundancy in this organism rendering
little loss in mycobacterial fitness despite disruption of the
genes. Accordingly, mutations easily arise under selection
pressure explaining the diversity of sequence variations
that have been observed in resistant mutants.14,19,25 The
exceptions are fbiC, where knockout mutants are found to
be hypersusceptible to oxidative stress generated by
selected naphthoquinones,26 and Ddn mutants where inac
tivation seems to affect the resuscitation of dormant
bacilli.25
Recent data also illustrate the importance of monitor
ing resistance to other agents in the approved regimen. The
rplC gene encodes ribosomal protein L3 which is involved
with antimicrobial binding,27 and rplC variants have been
reported to confer resistance to oxazolidinone (eg,
linezolid).28 In a recent study of induced dual resistant
(Iinezolid and pretomanid) MTB strains, variants in the
rplC gene occurred with high frequency (≥ 86%) and were
more virulent in mice.27 Monitoring for the emergence of
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resistance with clinical use of the BPaL regimen will be
essential.
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Emergence of Resistance
Several studies have examined the frequency of sponta
neous resistance to pretomanid in vitro (TB Alliance,
personal communication data).2,14,29 The data suggest
a mutation frequency (10−5 to 10−7) greater than that of
rifampin but comparable to other agents including isonia
zid, ethambutol, and pyrazinamide.30 Spontaneous muta
tion rates appear to be influenced by the concentration of
pretomanid to which the isolates are exposed and the
starting mycobacterial inoculum. Considering putative
mycobacterial loads at time of diagnosis and consistent
with the traditional approach to MTb treatment, pretoma
nid should be used in combination with other antimycobacterial agents.
The emergence of pretomanid resistance in treatment
has also been described in animal models,31,32 but data on
frequencies are limited. In BALB/c and C3HeB/FeJ mice
infected with MTb H37Rv via aerosol, investigators
observed a dose-dependent increase in spontaneous preto
manid-resistance.19 The spontaneous frequency of resis
tant mutants could not be estimated in untreated C3HeB/
FeJ mice because they succumbed early. However, BALB/
c mice demonstrated spontaneous resistance, in the
absence of pretomanid exposure, at a rate of ~10−5 and
the fraction of total CFU constituted by pretomanidresistant isolates increased in direct proportion with dose
up to 300 mg/kg.19 In a second study of 4- to 6-week-old
female BALB/c mice infected with MTb (strain H37Rv,
MIC 0.125 μg/mL), the proportion of CFU resistant to
pretomanid monotherapy after 2 months of treatment
(100 mg/kg) was 3.8×10−3.33 In combination with INH,
the proportion of CFU resistant to pretomanid dropped to
5.0×10−6.33 These data similarly highlight the potential for
selective amplification of pretomanid resistance. However,
the sponsor reported no emergence of resistance in the
human EBA studies (albeit with methodologic
limitations) (TB Alliance, personal communication data).
With respect to cross resistance, the sponsor examined
susceptibility profiles for 9 pretomanid resistant MTb
H37Rv strains (MGIT MIC > 16 μg/mL); 6 isolated
from the lungs of infected mice that had been treated
with pretomanid and 3 spontaneous mutants selected on
pretomanid-containing plates. Their study revealed that 8
of the 9 strains were found to be resistant to delamanid and
1 strain each was resistant to kanamycin and
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pyrazinamide. All 9 isolates remained susceptible to ami
kacin, bedaquiline, capreomycin, clofazimine, ethambutol,
ethionamide, isoniazid, linezolid, moxifloxacin, ofloxacin,
rifampin, and streptomycin (TB Alliance, personal com
munication data). Among 22 MDR and extremely drug
resistant (XDR) MTb isolates originating from the
Tuberculosis Biobank at the National Clinical Laboratory
on Tuberculosis (Beijing, China), 5 of 7 delamanidresistant isolates (MIC ≥16) were susceptible to pretoma
nid (MIC 0.016 to 0.063 mg/L).16 An additional 2 preto
manid-resistant isolates were susceptible to delamanid.
Pretomanid activity was also evaluated in MTb H37Rv
isolates, resistant to the more recently discovered nitrofur
anylamides (NFAs) and 5-nitrothiophenes (5NP) which
share structural features with pretomanid and delamanid.
Of 25 NFA-resistant isolates, 8 were cross resistant to
pretomanid, 11 were resistant to delamanid, and 7 were
resistant to both suggesting incomplete cross resistance
between these structurally similar compounds.34 All 11
of the 5NP-resistant isolates were fully cross-resistant to
pretomanid.35

Spectrum of Activity
Mycobacterium tuberculosis
Under routine culture conditions, minimum inhibitory con
centrations (MIC) for pretomanid against drug-susceptible
(DS), monoresistant, MDR, and XDR isolates of MTb
range from 0.005–0.48 μg/mL (TB Alliance, personal
communication data). These data suggest that resistance
phenotype has limited impact on pretomanid activity.
MICs increase approximately 3- to 4-fold in the presence
of 4% human albumin and more than 6-fold in the pre
sence of 50% human serum.36,37 Minimum bactericidal
concentrations (MBC) against MTb H37Rv under aerobic
conditions (0.02 μg/mL) are approximately twice that of
the MIC (0.01 μg/mL) while non-replicating mycobacteria
in low-oxygen conditions demonstrate an MBC (6.3 μg/
mL) approximately 7.5-fold higher than the MIC (0.82 μg/
mL) (TB Alliance, personal communication data).

Non-MTb Species
Pretomanid demonstrates activity against other species in
the Mycobacterium tuberculosis complex (MTBC)
including M. bovis, M. africanum, and M. pinnipedii
(MIC range <0.0312 to 0.125 μg/mL). Activity against
M. ulcerans (≤4 to ≥16 μg/mL) and M. canettii (8 μg/mL)
is reduced while no activity is seen against M. phlei,
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M. smegmatis, M. fortuitum, M. smegmatis, M. leprae
and M. avium complex (TB Alliance, personal commu
nication data).38 Activity against M. kansasii may be
reduced (8 µg/mL) or non-existent (TB Alliance, perso
nal communication data).38 When examined for activity
against commonly encountered non-mycobacterial spe
cies, pretomanid demonstrated no appreciable activity
against Streptococcus pneumoniae, S. pyogenes,
S. mutans, Staphylococcus aureus, S. epidermidis,
Enterococcus faecalis, E. faecium, Haemophilus influen
zae, Moraxella catarrhalis, Escherichia coli and
Enterobacter cloacae (MIC >128 μg/mL). Activity
against Candida albicans was also absent (MIC >50 μg/
mL) (TB Alliance, personal communication data).
When tested on a panel of anaerobic bacterial species
including gram-positive, gram-negative and microaerophi
lic, pretamonid was largely ineffective with MIC ranging
from 2 to >32.39 Pretamonid, and the structurally similar
metronidazole, were similarly ineffective against H. pylori
in this in vitro panel. Given that metronidazole is an
effective clinical tool against anaerobic infections, these
data should be interpreted with caution. Pretomanid activ
ity (MIC) against the various species were as follows:
C. difficile (2 ug/mL), L. acidophilus (>32 µg/mL),
G. vaginalis (>32 µg/mL), P. micros (<32 µg/mL),
P. asaccharolytica (2 µg/mL), P. acnes (>32 µg/mL), B.
fragilis (16 µg/mL), B. longum (>32 µg/mL), F. nucleatum
(4 µg/mL), M. mulieris (>32 µg/mL), P. bivia (32 µg/mL),
V. parvula (>32 µg/mL), H. pylori (16 µg/mL).

Pre-Clinical Activity
The intracellular activity of pretomanid against MTb (6.42
log10 CFU) has been investigated in macrophages differ
entiated from human THP-1 monocytes. Following 4
hours of drug exposure and an additional 68-hours of
culture, viable bacterial counts revealed that the intracel
lular potency of pretomanid appears comparable to isonia
zid (INH) and inferior to delamanid and rifampin by 3-fold
and 2-fold, respectively.40 Though intracellular: extracel
lular ratios vary by drug and incubation condition, average
extracellular (peak plasma) concentrations (µg/mL) are
0.2–0.6 (delamanid), 5–15 (rifampin), 1.1–2.2 (pretoma
nid), and 3–10 (isoniazid).41–43
In animal models, initial investigations into relative
NAP activity against a luminescent strain of MTb
H37Rv illustrated that pretomanid is as active as metroni
dazole and more active than its predecessor CGI 17341 or
isoniazid against static MTb.2 Early studies also examined
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the activity of pretomanid in a BALB/c murine model
where the same luminescent strain of MTb H37Rv was
injected by tail vein. These data offer evidence of a doseresponse relationship and allude to potency that is compar
able to INH.2 Subsequent dose ranging studies (3.125 to
200 mg/kg) in a BALB/c murine aerosol model set out to
establish the minimum effective dose (MED), defined as
the lowest dose capable of preventing the development of
gross lesions in the lung and spleen, and the minimum
bactericidal dose (MBD), defined as the lowest dose that
reduces lung CFU by 99%. In mice these were determined
to be 12.5 mg/kg and 100 mg/kg, respectively.33
Independent rapid in vivo screens confirmed ≥ 2 log10
CFU reductions in the lungs of both gamma interferon
knockout mice and immunocompetent C57BL/6 mice at
a dose of 100 mg/kg.44 Long-term in vivo screens further
demonstrated that at 100 mg/kg, pretomanid reduces the
CFU in lungs and spleens of C57BL/6 mice to the same
extent as INH (25 mg/kg), gatifloxacin (100 mg/kg) and
moxifloxacin (100 mg/kg). At lower doses, pretomanid
(50 mg/kg), INH (10 mg/kg), and rifampin (10 mg/kg)
each demonstrated comparable and persistent reductions
in CFU over a 4 month treatment window; however, 3
months post-treatment all mice receiving pretomanid or
INH relapsed, indicating a failure to achieve sterile cure
as a single agent.45 A combination regimen including
pretomanid (at 50 or 100 mg/kg) with bedaquiline and an
oxazolidinone (sutezolid or linezolid) led to CFU reduc
tions a full order of magnitude lower than can be achieved
with pretomanid alone, and complete or near complete
sterilization was observed in some cases (TB Alliance,
personal communication data).46,47
Initial estimates of pretomanid (40 mg/kg) activity in the
guinea pig model closely paralleled those observed in early
mouse models showing near equivalent reduction in myco
bacterium burden in the spleen and lung compared with
isoniazid (25 mg/kg).2 One additional investigation exam
ined various drugs alone and in combination in the guinea
pig model.48 In this study, distinctions between 3-drug regi
mens (vs dual or monotherapy) could be appreciated with
the combination pretomanid, moxifloxacin, and pyrazina
mide (PaMZ) demonstrating significantly greater reductions
in CFU compared with rifampin, isoniazid, pyrazinamide
(RHZ); however, by 2 months both groups were culture
negative. Among 2-drug regimens no clear distinctions
were observed.48
In an attempt to understand the relationship between
pretomanid exposure and response, time-kill kinetics of
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pretomanid against MTb H37Rv under aerobic conditions
were evaluated at concentrations ranging from 0.12 to 2.0
μg/mL (TB Alliance, personal communication data).
Based on these experiments, pretomanid appears to exhibit
both concentration- and time-dependent bactericidal activ
ity. Though only 2 concentrations were tested under anae
robic conditions (3 and 12.5 μg/mL), a similar observation
was noted (TB Alliance, personal communication data).
Dose fractionation studies were also conducted in BALB/c
mouse models.49 These studies attempted to disassociate
interdependent pharmacokinetic surrogates [ie, maximum
concentration to MIC ratio (Cmax/MIC), area-under-thecurve to MIC ratio (AUC/MIC), and percent of time spent
above the MIC (%T>MIC)] so as to identify the measure
most closely associated with bactericidal activity. In total,
31 different pretomanid dosing regimens were examined.
Among the surrogates evaluated, %T>MIC demonstrated
the strongest association with CFU counts in the lung (r2=
0.87), followed by AUC/MIC (r2= 0.60). Only a weak
association was observed with Cmax/MIC (r2= 0.17).49
Using these models and pharmacokinetic data from
Phase I studies, the investigators ran simulations exploring
putative %T>MIC values for pretomanid at MICs ranging
from 0.03125 to 0.25 μg/mL. At the labeled 200 mg dose,
pretomanid concentrations are predicted to spend over
two-thirds of the dosing interval above the MIC50.
Modeling and simulation have also been used to explore
the efficacy of pretomanid-containing regimens other than
the FDA-approved BPaL. Pretomanid plus moxifloxacin
appeared effective at eliminating MTB burden in vitro.50,51
In a recent exposure-response model-based meta-analysis
in mice, the addition of pretomanid to rifampicin and
bedaquiline reduced the simulated bacterial activity of
bedaquiline in multi-drug regimens; however, predicted
MICs were still within the range of susceptibility.52

Clinical Microbiology
Four clinical studies evaluated the early bactericidal activ
ity (EBA) of pretomanid in humans after 14 days of dosing
demonstrating that pretomanid was non-inferior to an iso
niazid, rifampin, pyrazinamide, ethambutol (HRZE) con
taining regimen (Table 1). Two additional studies
examined the EBA of pretomanid containing regimens
after 8 weeks of dosing and suggested that these outper
formed HRZE at 8 weeks (Table 1). Notably, none of the
regimens evaluated reflect the FDA approved BPaL regi
men. It should be noted that the data provided in the table
reflect those submitted as part of the NDA and the
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numbers are not entirely consistent with the data presented
on the ClinicalTrials.gov website or in the related study
publications.53–56 Per the sponsor, these discrepancies are
due to a change in the method used for calculating EBA
[personal communication K. Schostack]. The trends in the
data remain unchanged and the conclusions drawn are
largely unaffected. Recent modeling and simulation stu
dies using data from these early phase clinical trials (eg,
NC-002, NC-005, NC-006, Nix-TB) suggest that the
approved pretomanid dosing regimen (200 mg daily with
food) provides optimal exposure (eg, %T>MIC) compared
with alternate dosing schemes to meet efficacy endpoints
even after assuming wide inter-individual variability in
drug disposition.57,58

Pharmacology and Toxicology
The physicochemical properties of pretomanid are an
important determinant of its pharmacologic and toxicolo
gic effects. Pretomanid is a highly lipophilic compound
with low solubility.59 Based on the partition coefficient,
pretomanid is predicted to diffuse across lipid membranes
with minimal difficulty.

Absorption
The absolute bioavailability is suggested to be less than
50% based on oral and IV administration in male cyno
molgus monkeys. Cmax demonstrates wide interindividual
variability (%CV 127) in healthy volunteers60 with Tmax at
4–5 hours. After a single oral dose of 50–750 mg given to
healthy volunteers, systemic exposure increased to
approximately 55–80% of what would be expected if
truly dose proportional. A plateau in systemic exposure
was seen after single doses ≥1000 mg. After multiple
doses, pretomanid displayed an accumulation factor of ~2.
Tmax remained 4–5 hours across single or multiple doses.61
Two randomized, cross-over studies have been conducted
in healthy volunteers to assess the effect of food on the
pharmacokinetics of pretomanid. In contrast to non-human
primates, humans have markedly higher exposures to preto
manid if administered in the fed state compared with the
fasted state. In the first study, a 1000 mg dose was explored
administered as 5×200 mg tablets. In the second study, 50 mg
and 200 mg doses were examined each administered as an
individual 50 mg or 200 mg tablet.62 Pretomanid was admi
nistered after a 10-hour fast or a high-calorie, high-fat meal
with an 8-day washout between doses. At every dose (50,
200, 1000 mg), pretomanid exposures were elevated when
co-administered with a high-fat meal. The relative increase in
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Table 1 Clinical Studies Evaluating Early Bactericidal Activity (EBA) of Pretomanid in Humans
Study

Resistance

(Objective)

Phenotype

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 23.112.138.152 on 22-Jul-2021
For personal use only.

CL-010 (14d EBA)

CL-007 (14d EBA)

NC-001 (14d EBA)

NC-003 (14d EBA)

NC-002 (8 wk trial)

NC-005 (8 wk trial)

DS-TB

DS-TB

DS-TB

DS-TB

DS-TB or MDR-TB

DS-TB or MDR-TB

Regimen

n

Rate of Change in Sputum
CFU

TTP

Pa50
Pa100

15
15

0.060 (0.069)
0.099 (0.069)

2.78 (2.73)
5.82 (3.08)

Pa150

15

0.106 (0.085)

4.55 (3.76)

Pa200
HRZEBW

16
8

0.111 (0.074)
0.141 (0.054)

5.10 (3.25)
11.10 (4.78)

Pa200
Pa600

15
15

0.121 (0.067)
0.119 (0.044)

3.61 (3.09)
4.45 (3.16)

Pa1000

16

0.106 (0.089)

5.94 (3.84)

Pa1200
HRZEBW

15
8

0.127 (0.084)
0.133 (0.061)

5.82 (3.39)
9.71 (4.76)

Pa200 M400 ZBW
Pa200 ZBW

15
15

0.233 (0.128)
0.153 (0.040)

18.48 (22.58)
8.81 (3.47)

B700>400 Pa200
B700>400 ZBW

15
15

0.114 (0.050)
0.134 (0.102)

5.86 (2.79)
9.97 (6.99)

B700>400

15

0.065 (0.068)

5.41 (3.52)

HRZEBW

10

0.140 (0.094)

11.84 (3.93)

B400>200 Pa200 Z1500 C300>100
B400>200 Pa200 Z1500
B400>200 Pa200 C300>100

15
15
15

0.111 [0.037,0.184]
0.167 [0.078,0.256]
0.076 [0.007,0.147]

0.026 [0.017,0.035]
0.029 [0.017,0.035]
0.017 [0.010, 0.023]

B400>200 Z1500 C300>100
Z1500

15
15

0.119 [0.031,0.211]
0.037 [−0.025,0.100]

0.021 [0.014, 0.030]
0.008 [0.003, 0.014]

C300>100

15

0.017 [−0.086,0.055]

−0.001 [−0.006, 0.005]

HRZEBW

15

0.151 [0.070,0.231]

0.027 [0.021, 0.032]

Pa100 M400 Z1500
Pa200 M400 Z1500
HRZEBW

60
62
59

0.133 [0.109,0.155]
0.155* [0.133,0.178]
0.112 [0.093,0.131]

0.020 [0.015,0.025]
0.020 [0.016,0.024]
0.017 [0.013,0.021]

Pa200 M400 Z1500

26

0.117 [0.070,0.174]

0.015 [−0.001,0.031]

B200 Pa200 Z1500
B400>200 Pa200 Z1500
HRZEBW

60
59
61

0.109 [0.097,0.121]
0.123 [0.109,0.139]
0.116 [0.106,0.127]

5.17* [4.61,5.77]
4.87* [4.31,5.47]
4.04 [3.67,4.42]

B200 Pa200 M400 Z1500

60

0.156* [0.125,0.198]

5.18* [4.60,5.83]

Notes: Data are presented as mean (SD) [CI]. B700>400700 mg day 1, 500 mg day 2, 400 mg days 3–14; B400>200 either 400 mg day 1, 300 mg day 2, 200 mg days 3–14 (NC003) or 400 mg days 1–14, 200 mg days 15–56 (NC-005); C300>100300 mg day 1–3, 100 mg days 4–14. *Statistically different from HRZE.
Abbreviations: Pa, pretomanid; B, bedaquiline; M, moxifloxacin; Z, pyrazinamide; C, clofazimine; H, isoniazid; R, rifampicin; E, ethambutol.

bioavailability gets disproportionately larger with increasing
dose, likely accounted for by an overall reduction in bioavail
ability (less than proportional increase in exposure) at higher
doses in the fasted state. Only nominal changes in Tmax and
half-life were observed. Thus, at the labeled dose of 200 mg,
average increases of 76% in Cmax and 88% in AUC can be
expected. A recent study suggests that this increased expo
sure in the fed state may be leveraged to negate the reduction
expected with co-administration of rifampin.63

Drug Design, Development and Therapy 2021:15

Distribution
Pretomanid is distributed throughout the body (Vd/F 92–
180 L) (TB Alliance, personal communication data)64 and
enters the central nervous system.65 Pretomanid is moder
ately protein bound in human plasma, mainly to albumin,
ranging from 86.3 to 86.5%.66 The ratio of pretomanid in
blood to plasma was examined in two studies and found to
be less than 1, suggesting a low potential for partitioning
into red blood cells. Across three concentrations (2.5–10
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µg/mL), ratios ranged from 0.66–0.83 Kb/p and 0.31–0.68
Ke/p.66

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 23.112.138.152 on 22-Jul-2021
For personal use only.

Metabolism
Pretomanid undergoes phase I and phase II biotransforma
tion by multiple metabolic pathways (eg, oxidation, nitro
reduction, oxidative deamination, oxidative cleavage, gly
cine conjugation, glucuronidation66) resulting in numerous
metabolites. The most abundant metabolite identified in
primary human hepatocytes is the trifluoromethoxybenzoic acid glycine conjugate; however, very little drug
was transformed in this in vitro study (5–8%) as compared
with the extensive biotransformation seen in humans (<1%
unchanged in urine).
Among the cytochromes P450 (CYP), CYP3A4
appears to account for up to 20% of pretomanid biotrans
formation, a contribution that is abolished in the presence
of the strong CYP3A4 inhibitor, ketoconazole. Other
microsomal enzymes may contribute to pretomanid meta
bolism, although studies in recombinant enzymes suggest
that CYP2C9, CYP2C19, and CYP2D6 play a negligible
role.66 Clearance may be saturable at high concentrations
above those expected with labeled dosing (>600 mg/
daily),60 and no data are yet available for individuals
with impaired liver function, though that study is forth
coming as requested by the FDA.
With respect to drug-drug interaction potential, the
ability of pretomanid to inhibit phase I metabolic path
ways, directly and in a time-dependent manner, has been
investigated. In vitro, pretomanid demonstrates the poten
tial to directly inhibit CYP3A4/5 up to 91%66 at concen
trations in excess of those observed with routine dosing.
A downward shift in IC50 under time-dependent conditions
is seen for several drug-metabolizing enzymes and sug
gests a potential for CYP3A, CYP2C8, and CYP2C19
mediated drug-drug interactions. In contrast, the recorded
IC50 values for CYP1A2 and CYP2D6 (>100 μM) suggest
that no clinically significant inhibition is expected for their
substrates. The potential for pretomanid to induce phase
I DME was also evaluated in primary human hepatocytes
from 4 individual donors. CYP3A4 and CYP2C9 induc
tion appears to be negligible at clinically relevant concen
trations. The large degree of variability for CYP2E1 makes
the findings inconclusive. CYP2D6, CYP2A6, and
CYP2C19 have not been tested.66
A limited number of healthy volunteer studies are
available exploring the in vivo impact of the potential for
these drug-drug interactions identified in vitro. One study
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details the impact of CYP3A inducers (efavirenz, lopina
vir/ritonavir, rifampin) on the disposition of pretomanid67
and two studies examined the impact of pretomanid on
CYP3A4 substrates (midazolam, efavirenz, lopinavir/
ritonavir).67,68 In healthy volunteers, coadministration of
pretomanid with the CYP3A4 inducer rifampin reduces
pretomanid exposure by over 50%. The CYP3A4 inducer
efavirenz reduces pretomanid exposures by ~30% whereas
exposures drop by less than 20% when co-administered
with the weak inducer lopinavir/ritonavir. When the
impact of pretomanid is measured on co-administered
CYP3A substrates, there is no appreciable effect on efa
virenz or lopinavir/ritonavir. At a dose twice that recom
mended by the FDA, modest induction of midazolam is
observed as evidenced by both a reduction in the parent
compound and an increase in the formation of its CYP3A
mediated metabolite, 1ʹ-hydroxy midazolam. The clinical
impact of this observation is likely limited and the FDA
concludes that pretomanid can be administered with other
CYP3A substrates. However, co-administration should be
avoided with rifampin, efavirenz, or other moderate to
strong inducers of CYP3A4.
Two additional studies in rats examined the disposition
of pretomanid, moxifloxacin, pyrazinamide, and darunavir
alone and in combination.69,70 Darunavir demonstrates
strong induction of pretomanid which likely occurs at the
level of CYP3A. In contrast, the mechanism behind the
moderate increase in moxifloxacin and pretomanid expo
sures that are observed in rats when the drugs are coadministered as PaMZ is unclear. Enhanced bioavailability
is a plausible mechanism for pretomanid but would not
explain the increase in exposure for moxifloxacin which is
well absorbed in the absence of other medications.
Whether linearity is compromised at the doses studied, or
this reflects a species-specific interaction is unclear.

Excretion
In healthy volunteers, approximately 53% of the total dose
is recovered in the urine, of which very little is unchanged
drug (1%). Nearly 38% of the total dose is recovered in
feces. The elimination half-life is ~17 hours regardless of
food conditions. Data are not currently available for indi
viduals with impaired renal function, but such studies have
been requested by the FDA and are in progress. A steady
state dose escalation study of pretomanid identified
a relationship between trough concentrations of the drug
and increased circulating serum creatinine levels (R2=
0.59) with a subsequent decline after discontinuation of
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the drug. In contrast, there was no consistent change in
blood urea nitrogen levels.61 The authors subsequently
attempted to explore the mechanism behind these findings,
specifically whether there were corresponding increases in
protein catabolism or reductions in renal function.71 The
follow-up study suggests that these changes are likely the
result of inhibition of creatinine secretion at the level of
the renal proximal tubule.

Transport
In considering transport, pretomanid does not appear to be
a substrate for OAT1, OAT3, OCT2, OATP1B1,
OATP1B3, MATE1, MATE2-K, BCRP or P-gp based on
in vitro transporter assays in MDCK-II cells and
MDCK_MDR1 cells.66 Inhibition by pretomanid of the
aforementioned transporters was also evaluated in vitro.
At clinically relevant concentrations, pretomanid inhibits
the renal tubular uptake transporter OAT3 which could
reduce the clearance of substrate drugs (eg, antibiotics,
antivirals, H2-receptor antagonists, diuretics, NSAIDs, sta
tins, uricosurics, and methotrexate). Inhibition of MATE2K at clinically relevant concentrations is less likely while
no inhibition is expected for OAT1, OCT1, OCT2,
OAT1B1, OATP1B3, BCRP, BSEP, P-gp, and MATE1
(TB Alliance, personal communication data).66

Toxicology
The majority of data regarding potential toxic effects of
pretomanid comes from in vitro and preclinical studies. No
mutagenic or clastogenic effects of pretomanid were
detected in Ames assays (5000 μg/plate), Chinese hamster
ovary cell assays (up to 1000 μg/mL), in vitro mouse
lymphoma assays (up to 500 μg/mL), and in vivo mouse
micronucleus assays (up to 2000 mg/kg/day). However,
the hydroxy imidazole metabolite (M50) which accounts
for ~6% of the human pretomanid exposure, was positive
on Ames testing.66 No significant increase in the incidence
of lung tumors, hemangiosarcoma, nonvascular tumors,
and other tumors was found after 26-weeks of daily pre
tomanid dosing in TG.rasH2 mice (TB Alliance, personal
communication data). A post-marketing 2-year carcino
genicity study in rats has recently been completed and is
under regulatory review at the time of this publication.
Long-term safety data in humans are not yet available but
will shed light on carcinogenicity and mutagenicity with
clinical use of pretomanid.
At exposure most relevant to labeled dosing in
humans, organ specific safety signals from animal studies
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demonstrate the potential for hepatic, ophthalmologic
and reproductive toxicity (TB Alliance, personal commu
nication data).66 A dose-dependent increase in liver
weight without histopathological findings was seen in
non-human primates and the no-observed-adverse-eventlevel (NOAEL) was set at 1.5x human exposure. Murine
studies demonstrated hepatic hypertrophy and limited
liver transaminase elevations with NOAEL at 7x human
exposure. Mixed ophthalmological findings in nonhuman primates led to NOAEL of 100 mg/kg/day
(~2.6x human exposure). In rats, 20% developed catar
acts at various dosing schemes and ultimately the
NOAEL was set to 30 mg/kg/day (~1.5x human expo
sure); however, cataracts were not seen in monkeys at 1–
2x human exposure. Neurological findings, eg, seizures
and ataxia, were present in short-term high dose studies
(eg, 2 weeks at 1000 mg/kg/day) in non-human primates,
but rarely present in long-term studies. The NOAEL was
set at 50 mg/kg/day (~1.3x human exposure).
QTc prolongation is not expected at labeled dosing.
A dose-dependent increase in QTc was observed in nonhuman primates with NOAEL set at 150 mg/kg (4x human
exposure). This finding appears consistent with an in vitro
cardiac safety screen (hERG current inhibition) demonstrat
ing an IC50 equivalent to 3x Cmax in plasma at labeled doses.
One study used modeling and simulation to evaluate the
impact of pretomanid alone and in combination (BPaL) on
QTc interval using data from 8 clinical trials submitted in the
NDA. Although a positive exposure-response relationship
was found, <10 ms increase is expected at maximum plasma
concentrations seen with labeled dosing.72
According to initial FDA review documents, the testicu
lar toxicity in monkeys was set to 50 mg/kg;66 however,
more recent data from the sponsor report an NOAEL of
100 mg/kg/day (~2.6x human exposure) with no abnormal
testicular findings after 9 months of dosing in monkeys. The
NOAEL for maternal and embryo-fetal effects in rats was
10 mg/kg and 30 mg/kg, respectively and in rabbits was
10 mg/kg and 60 mg/kg, respectively. In lactating dams
treated with a regimen thought to be equivalent to human
exposure, a single point estimate of pretomanid revealed
a higher concentration in milk (1.6 µg/mL) compared with
plasma (1.1 µg/mL). At regimens equivalent to 2–4x human
exposure, concentrations in milk were 59–68% of plasma
concentrations. These data merit discussions of off-label use
in children and pregnant females. No lactation data are yet
available in humans and alternative therapy may be consid
ered until more is known.73 The FDA has required a post-
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marketing human semen study and, once available, data can
inform clinical discussions with males of reproductive age.
Shared decision-making regarding treatment of MDR/
XR-TB with a pretomanid-containing regimen should
involve discussion of the potential pretomanid toxicity
based on limited animal data weighed carefully against
the risk of untreated TB infection. For pregnant adults
specifically, it is important to acknowledge the known
adverse maternal and fetal outcomes associated with
untreated tuberculosis74 while balancing the unknown ter
atogenic and developmental effects of pretomanid.
Because of the lack of data, the WHO does not currently
recommend use of pretomanid in pregnancy.

Efficacy and Safety
For the initial review of the new drug application (NDA),
the FDA assessed interim data from the NIX-TB trial for
participants who had completed the 6-month posttreatment follow up or died (n=45). The efficacy data in
the NDA were updated throughout the review and based
primarily on n=81 participants available by an interim data
cut-off date. Data from all participants who received pre
tonamid (n=109) were available prior to full approval.66
The NIX-TB trial (n=109) enrolled participants with
XDR-TB (65%) and MDR-TB (35%). Fifty-one percent
of the participants were HIV+. In the intention-to-treat
(ITT) analysis, favorable outcomes were 90% and 88%

at 6 months and 24 months, respectively, and not influ
enced by sex and HIV status (Table 2).75,76 A recent case
study describes the successful treatment of MDR-TB using
a lower linezolid dynamic dosing based on an exposure
target of 600 mg/d vs 1200 mg/d in combination with
pretamonid and bedaquiline.77 Similar regimens are cur
rently being evaluated in the ZeNix trial. Table 3 lists
ongoing trials for pretomanid-containing regimens, some
of which include pediatric patients. No efficacy data are
yet available for these trials at the time of this review.
In the completed NIX-TB trial, all 109 participants
(100%) experienced at least 1 treatment emergent adverse
event (TEAE), nearly all of which were considered related
to study drug (99%). In 19 subjects (17.4%) 36 serious
TEAEs were reported, with infection being most promi
nent (11 events). One event each of mild optic neuropathy
and elevated transaminases was reported.75 No grade ≥3
ophthalmic TAEs were reported and there was no evidence
of cataracts detected by slit lamp examinations associated
with pretomanid.75 All surviving participants were able to
complete the full course of therapy with some interrup
tions due to adverse events, and no adverse-event related
withdrawal. The STAND trial, which evaluated pretoma
nid, moxifloxacin, and pyrazinamide compared with stan
dard treatment (HRZE), found more than a 2-fold higher
rate in gastrointestinal (nausea, vomiting, diarrhea) and
pulmonary (pleuritic pain, hemoptysis, URI) adverse

Table 2 Efficacy of Pretomanid-Containing Regimens
Trial

NIX-TB^

Regimen

Pa200 QD, B400 QD x 2 weeks then B200 3x/week,
L1200 QD X 30 weeks

Phenotype

mITT at 6 Months

PP

Favorable

Unfavorable

Favorable

Unfavorable

XDR (n=71)

63* (90%)

7 (10%)

62 (91%)

6 (9%)

TI/NR MDR

35 (95%)

2(5%)

35 (95%)

2 (5%)

(n=38)
STAND

Pa100 M400 Z1500 X 17 weeks

DS-TB

38 (66.7%)

19 (33.3%)

38 (73.1%)

14 (26.9%)

STAND

Pa200 M400 Z1500 X 17 weeks

DS-TB

46 (75.4%)

15 (24.6%)

46 (80.7%)

11 (19.3%)

STAND

Pa200 M400 Z1500 X 26 weeks

DS-TB

43 (76.8%)

13 (23.2%)

43 (91.5%)

4 (8.5%)

STAND

H75 R150 Z400 E275 X 8 wks; H75 R150 wks 9 to 26

DS-TB

52 (86.7%)

8 (13.3%)

52 (98.1%)

1 (1.9%)

STAND

Pa200 M400 Z1500 X 26 weeks

MDR-TB

10 (90.9%)

1 (9.1%)

10

0 (0.0%)

(100.0%)
Notes: *The following categorical variables had no appreciate impact on mITT: HIV status, linezolid regimen (600 mg BID or 1200 QD), age (above or below median),
gender, race (black vs white/other), cavitation, TTP at baseline from MGIT (above or below median). ^NIX-TB- Two exclusions in mITT resulting in total n=107 (non-TB
related death in follow up and lost to follow up after end of treatment). Two additional exclusions in PP resulting in total n=105 (one inadequate amount of drug and one
withdrawn not for treatment failure).
Abbreviations: mITT, modified intention to treat; PP, per protocol.
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Table 3 Ongoing Clinical Trials of Pretomanid-Containing Regimens for TB
Trial

Design

Drug

Comparator

Population

Regimens

Primary

Expected/

Outcome(s)

Reported

Clinical Trial

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 23.112.138.152 on 22-Jul-2021
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Completion
Date
ZeNix

Multicenter,
partially-

BPaL1200
BPaL1200

blinded (Z

BPaL600

x 26 wk

only),
randomized,

BPaL600

x 9 wk

x 26 wk

n/a

x 9 wk

Phase III

MDR-TB,
XDR-TB or

Incidence of
bacteriologic failure or

pre-XDR-

relapse or clinical failure

TB, target
enrollment

through follow up until
26 weeks after the end

n=180; ≥14

of treatment

12/2021

NCT03086486

4/2020

NCT03338621

Early 2023

NCT02589782

yrs
SimpliciTB

DS-TB and

Time to culture

open-label,
partially

DR-TB,
n=455; ≥18

conversion to negative
status over 8 weeks

randomized,

yrs

Multicenter,

BPaMZ

HRZE or HR

phase IIc
TBPRACTECAL

MDR-TB,
target

Stage 1: % culture
conversion in liquid

multi-arm,

enrollment

media at 8 wks

randomized,
controlled,

n=630; ≥15
yrs

Stage 1: %treatment
discontinuation for any

Multicenter,
open label,

BPaML or
BPaCL or BPaL

Locally
accepted SOC

Phase II–III

reason

trial

Stage 2: % unfavorable
outcome

Abbreviations: B, bedaquiline; C, clofazimine; DR-TB, drug resistant tuberculosis; DS-TB, drug susceptible tuberculosis; E, ethambutol; H, isoniazid; L, linezolid; M,
moxifloxacin; MDR-TB, multidrug resistant tuberculosis; Pa, pretomanid; R, rifampicin; SOC, standard of care; XDR-TB, extensively resistant tuberculosis; Z, pyrazinamide.

events. Transaminase elevations along with the elevation
of other LFTs were seen with moderate frequency among
the non-serious AEs but at a rate comparable to HRZE.
Three hepatotoxicity associated deaths initially prompted
study suspension, but the study was allowed to resume
after independent review by the drug safety monitoring
committee. Overall, a higher rate of unfavorable outcomes
for the primary measure compared with HRZE and failed
non-inferiority criterion prompted early termination of the
STAND trial.78
Safety data from ongoing trials (Table 3) are not yet
publicly available. A recent Phase 2b study in drugsusceptible or rifampin-resistant TB found that both preto
manid regimens outperformed standard therapy (HRZE) in
the primary outcome, but also had higher rates of disconti
nuation due to adverse events (8–10% vs 3%). Serious
adverse events occurred in two participants (3%) receiving
BloadPaZ and one participant (2%) receiving HRZE.
Preliminary efficacy and adverse event data from this
Phase 2b study argue for continued study of B200PaZ in

Drug Design, Development and Therapy 2021:15

drug susceptible TB, particularly given its shorter duration
of therapy and simplified dosing scheme (once daily).79
When the regimens are broadly combined and treatmentemergent non-serious adverse events are evaluated against
a standard HRZE regimen (Table 4), neurologic and hepatic
disturbances appeared to be more prevalent in the pretomanid
containing regimens with arthralgias and gastrointestinal
events more prevalent in the moxifloxacin containing regi
mens. Pretomanid alone (n=411) results in minimal liver
toxicity with only 2.2% of individuals experiencing ALT or
AST >5 x ULN, or total bilirubin >2 x ULN compared with
5.6–11.7% in pretomanid containing combination regimens
and 6.5% in control or placebo regimens. These safety data
suggest that liver toxicity is largely related to other anti-TB
medications.80 Ascribing clinical trial related ADRs to pre
tomanid is confounded by the lack of long-term administra
tion data for pretomanid alone. Headache may be attributed
to pretomanid as it occurred more frequently in patients
receiving pretomanid alone than control (31.5% vs 22.9%)
and occurred more frequently at higher pretomanid doses
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Table 4 Treatment Emergent Adverse Events for Various Regimens
Regimen

PaMZ n=148

BPaZ n=119

BPaMZ n=60

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 23.112.138.152 on 22-Jul-2021
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Trial

BPaL n=109

HRZE n=120

NIX-TB

Nausea

30 (20.3%)

4 (3.4%)

5 (8.3%)

40 (36.7%)

8 (6.7%)

Vomiting

18 (12.2%)

5 (4.2%)

7 (11.7%)

37 (33.9%)

11 (9.2%)

Diarrhea

10 (6.8%)

4 (3.4%)

3 (5%)

11 (10.1%)

3 (2.5%)

Abdominal pain/dyspepsia

9 (6.1%)

37 (34%)

3 (2.5%)

Decreased appetite

24 (22.0%)

Abnormal weight loss

11 (10.1%)

Liver disorder
Enzyme abnormality

33 (22.3%)

9 (7.5%)

7 (4.7%)

4 (3.3%)

ALT increased

8 (6.7%)

2 (3.3%)

10 (9.2%)

2 (1.7%)

AST increased

6 (5%)

3 (5%)

9 (8.3%)

3 (2.5%)

Amylase increased

10 (16.7%)

1 (0.8%)

GGT increased

2 (1.7%)

6 (10%)

19 (17.4%)

Anemia

5 (4.2%)

1 (1.7%)

40 (36.7%)

Leukocytosis

9 (6.1%)

3 (2.5%)

Hyperkalemia or hyponatremia

13 (8.8%)

8 (6.7%)

Glucose abnormality
Hypoalbuminemia

9 (6.1%) - hyper

12 (11%)-hypo

6 (4.1%)

3 (2.5%)- hyper
5 (4.2%)

Hyperuricemia

42 (28.4%)

28 (23.5%)

27 (45%)

26 (21.7%)

Dizziness

15 (10.1%)

4 (3.4%)

1 (1.7%)

5 (4.2%)

Headache

14 (9.5%)

30 (27.5%)

Peripheral sensory neuropathy*

76 (69.7%)

Myalgia
Arthralgia

2 (1.7%)

38 (25.7%)

Extremity or back pain

7 (5.9%)

3 (5%)

1 (0.8%)

15 (12.6%)

13 (21.7%)

17 (14.2%)

2 (1.7%)

4 (6.7%)

Acne

13 (11.9%)
17 (15.6%)

Rash

3 (2.5%)

1 (1.7%)

Pruritus generalized

8 (6.7%)

2 (3.3%)

5 (4.2%)

2 (3.3%)

16 (14.7%)

4 (3.4%)

6 (10%)

14 (12.8%)

6 (10%)

14 (12.8%)

Pruritis

8 (5.4%)

Hemoptysis
Pleuritic/non-cardiac chest pain
UTI

2 (1.7%)

4 (6.7%)

17 (15.6%)

2 (1.7%)
8 (6.7%)
8 (6.7%)

2 (1.7%)

Notes: *Peripheral sensory neuropathy includes related codes (eg, neuropathy peripheral, paresthesia, hypoesthesia, peripheral motor neuropathy, burning sensation,
hyporeflexia, peripheral sensorimotor neuropathy).
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(45.6% in those receiving >200 mg) (TB Alliance, personal
communication data). No participants experienced arthralgia,
hyperuricemia, hepatic enzyme elevations, hyperuricemia,
hyperglycemia, somnolence, anemia, pruritic rash, photo
phobia, visual acuity disturbance, hematuria, proteinuria,
breast disorders or death when taking pretomanid alone
(n=122). Nausea occurred in 4.1% of pretomanid only
group vs 6.1% in HRZE control group (TB Alliance, perso
nal communication data). For individuals receiving the BPaL
regimen, expert consensus suggests that hepatic enzyme
elevations, lens disorders, dermatitis, GI upset, and severe
cutaneous adverse reactions are more likely to be attributed
to pretomanid rather than the other regimen components.

Special Populations
Current WHO recommendations highlight several special
populations that deserve careful consideration before pre
tomanid use. No data are yet available for pretomanid use
in children <14 years old, pregnant or lactating women,
and medications with more established safety profiles are
recommended for use at this time. Breastfeeding is not
recommended when taking BPaL. For individuals living
with HIV, concomitant antiretroviral therapy should be
assessed and efavirenz avoided if possible due to reduced
pretomanid exposure. Those taking zidovudine along with
the BPaL regimen are at additive risk for peripheral nerve
toxicity and myelosuppression from linezolid (rather than
pretomanid). Although no data currently exist for preto
manid use in extrapulmonary TB, treatment recommenda
tions are unchanged for individuals with extrapulmonary
manifestation of MDR-TB, including TB meningitis.
Finally, for individuals with life-threatening extensive
drug resistant TB that prevents the application of WHO
guideline-based treatment, BPaL may be considered “as
a last resort under prevailing ethical standards.”81

Conclusion
Drug resistant MTB strains are difficult to treat, continue to
emerge, and threaten global progress in combatting TB.81
The global clinical development pipeline for new anti-TB
medicines has less than a dozen new drugs at the early
stages of research.82 Since drug development is known to
have particularly high attrition rates, only a few of these
candidates may reach the market. This status quo and the
fact that there were only three new medicines developed for
TB treatment in the last 70 years make every emerging antiTB medicine an important and valuable asset.
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Following bedaquiline and delamanid, pretomanid is
the third recently approved medicinal agent for use in
TB patients as part of the regimen also including bedaqui
line and linezolid (BPaL). This 6-month regimen brings
a new perspective of shortening treatment for drugresistant TB and a shift from the currently recommended
lengthy and difficult to tolerate and adhere to regimens,
that usually last 9 to 20 months, to ones that are shorter
and easier to implement. The BPaL regimen is condition
ally recommended by WHO to be used under operational
research framework that precludes its wider, programmatic
use.81 However, the advent of the new medicine – preto
manid, as part of the BPaL regimen and the new guidance
from WHO, have already stimulated a massive number of
research studies that promise to bring additional evidence
that may support broader and stronger recommendations
on its use. Additionally, evaluation of cost-effectiveness of
the BPaL is ongoing.83
In summary, pretomanid is part of a novel multi-drug
regimen for MDR/XR-TB that allows for a shorter dura
tion of therapy. Using shared decision making, counseling
regarding benefits and risks may include the possibility of
infertility through alterations in spermatogenesis and lack
of safety and toxicology data in pregnant patients and
breastfed infants. Additional forthcoming data will
improve our understanding of the safety, efficacy, and
use of pretomanid in TB.
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